Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec
We report on the findings of an original research initiative to explore current gaps that exist in the level of awareness and utilization of Canada's adverse drug reaction (ADR) reporting system among community pharmacists. To understand the level of knowledge and practices related to ADR repor...
Gespeichert in:
| Veröffentlicht in: | Drug information journal 2011-09, Vol.45 (5), p.627-639 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 639 |
|---|---|
| container_issue | 5 |
| container_start_page | 627 |
| container_title | Drug information journal |
| container_volume | 45 |
| creator | Rouleau, Benoît Lavoie, Louise Leblanc, Jacinthe Moretti, Simon Collin, Chantal |
| description | We report on the findings of an original research initiative to explore current gaps that exist in the level of awareness and utilization of Canada's adverse drug reaction (ADR) reporting system among community pharmacists. To understand the level of knowledge and practices related to ADR reporting, a survey was conducted among Quebec pharmacists. Nearly two thirds of respondents had reported at least one ADR in the past, but many did not recognize “lack of effectiveness” as an ADR and were unaware of the minimum requirements for ADR reporting. Events seen as “unexpected, rare, or serious” were most likely to be reported whereas “well-known or common” events or those with “uncertain causality” tended not to be reported. Regarding switching from brand name to generic formulation, two thirds reported that they did not perform special monitoring, yet the same proportion recalled a specific ADR associated with switching, particularly with Effexor XR (venlafaxine XR), Pantoloc (pantoprazole), and Concerta (methylphenidate-OROS). The majority of the current survey participants (Quebec pharmacists) are aware of the ADR reporting system, but underutilization exists. |
| doi_str_mv | 10.1177/009286151104500613 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_910018602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_009286151104500613</sage_id><sourcerecordid>2551244131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-53e0d290cb07c5efab817bf38a107a434264b1f3e98f042fb52a2e9d43dec6f33</originalsourceid><addsrcrecordid>eNqNkEtLw0AUhQdRsFb_gKtB17H3zkxe7kp9QkGtunIRJsmdmmKTOjMp5N-b0oILUVxdOHzfuXAYO0W4QIzjEUAqkghDRFAhQIRyjw0ERipIBcA-G2yAYEMcsiPnFgAChEoH7G1Gq8b6qp7zxvBxuSbriF_Zds5npAtfNbXjeccnzXLZ1pXv-OO7tktdVM67Sz7mT63-qLz21Zr4s2_Ljld1H1JOxTE7MPrD0cnuDtnrzfXL5C6YPtzeT8bToJBJ5INQEpQihSKHuAjJ6DzBODcy0QixVlKJSOVoJKWJASVMHgotKC2VLKmIjJRDdrbtXdnmsyXns0XT2rp_maUIgEkEoofOf4NEGKJQCiX2lNhShW2cs2Syla2W2nYZQrZZOvu5dC_JreR6uJ6T_a7-0xrtLD2nfxlfFUiLyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>910018602</pqid></control><display><type>article</type><title>Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec</title><source>SpringerNature Journals</source><source>SAGE Journals</source><creator>Rouleau, Benoît ; Lavoie, Louise ; Leblanc, Jacinthe ; Moretti, Simon ; Collin, Chantal</creator><creatorcontrib>Rouleau, Benoît ; Lavoie, Louise ; Leblanc, Jacinthe ; Moretti, Simon ; Collin, Chantal</creatorcontrib><description>We report on the findings of an original research initiative to explore current gaps that exist in the level of awareness and utilization of Canada's adverse drug reaction (ADR) reporting system among community pharmacists. To understand the level of knowledge and practices related to ADR reporting, a survey was conducted among Quebec pharmacists. Nearly two thirds of respondents had reported at least one ADR in the past, but many did not recognize “lack of effectiveness” as an ADR and were unaware of the minimum requirements for ADR reporting. Events seen as “unexpected, rare, or serious” were most likely to be reported whereas “well-known or common” events or those with “uncertain causality” tended not to be reported. Regarding switching from brand name to generic formulation, two thirds reported that they did not perform special monitoring, yet the same proportion recalled a specific ADR associated with switching, particularly with Effexor XR (venlafaxine XR), Pantoloc (pantoprazole), and Concerta (methylphenidate-OROS). The majority of the current survey participants (Quebec pharmacists) are aware of the ADR reporting system, but underutilization exists.</description><identifier>ISSN: 0092-8615</identifier><identifier>ISSN: 2168-4790</identifier><identifier>EISSN: 2164-9200</identifier><identifier>EISSN: 2168-4804</identifier><identifier>DOI: 10.1177/009286151104500613</identifier><identifier>CODEN: DGIJB9</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Brand names ; Drug Information ; Drug Safety and Pharmacovigilance ; Drug stores ; Education ; Methylphenidate ; Pharmaceuticals ; Pharmacists ; Pharmacotherapy ; Pharmacy ; Polls & surveys ; Qualitative research ; Safety ; Side effects ; Switching ; Venlafaxine</subject><ispartof>Drug information journal, 2011-09, Vol.45 (5), p.627-639</ispartof><rights>2011 Drug Information Association</rights><rights>Drug Information Association, Inc 2011</rights><rights>Drug Information Association, Inc 2011.</rights><rights>Copyright Drug Information Association Sep 2011</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-53e0d290cb07c5efab817bf38a107a434264b1f3e98f042fb52a2e9d43dec6f33</citedby><cites>FETCH-LOGICAL-c386t-53e0d290cb07c5efab817bf38a107a434264b1f3e98f042fb52a2e9d43dec6f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/009286151104500613$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/009286151104500613$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids></links><search><creatorcontrib>Rouleau, Benoît</creatorcontrib><creatorcontrib>Lavoie, Louise</creatorcontrib><creatorcontrib>Leblanc, Jacinthe</creatorcontrib><creatorcontrib>Moretti, Simon</creatorcontrib><creatorcontrib>Collin, Chantal</creatorcontrib><title>Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec</title><title>Drug information journal</title><addtitle>Ther Innov Regul Sci</addtitle><description>We report on the findings of an original research initiative to explore current gaps that exist in the level of awareness and utilization of Canada's adverse drug reaction (ADR) reporting system among community pharmacists. To understand the level of knowledge and practices related to ADR reporting, a survey was conducted among Quebec pharmacists. Nearly two thirds of respondents had reported at least one ADR in the past, but many did not recognize “lack of effectiveness” as an ADR and were unaware of the minimum requirements for ADR reporting. Events seen as “unexpected, rare, or serious” were most likely to be reported whereas “well-known or common” events or those with “uncertain causality” tended not to be reported. Regarding switching from brand name to generic formulation, two thirds reported that they did not perform special monitoring, yet the same proportion recalled a specific ADR associated with switching, particularly with Effexor XR (venlafaxine XR), Pantoloc (pantoprazole), and Concerta (methylphenidate-OROS). The majority of the current survey participants (Quebec pharmacists) are aware of the ADR reporting system, but underutilization exists.</description><subject>Brand names</subject><subject>Drug Information</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Drug stores</subject><subject>Education</subject><subject>Methylphenidate</subject><subject>Pharmaceuticals</subject><subject>Pharmacists</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Polls & surveys</subject><subject>Qualitative research</subject><subject>Safety</subject><subject>Side effects</subject><subject>Switching</subject><subject>Venlafaxine</subject><issn>0092-8615</issn><issn>2168-4790</issn><issn>2164-9200</issn><issn>2168-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkEtLw0AUhQdRsFb_gKtB17H3zkxe7kp9QkGtunIRJsmdmmKTOjMp5N-b0oILUVxdOHzfuXAYO0W4QIzjEUAqkghDRFAhQIRyjw0ERipIBcA-G2yAYEMcsiPnFgAChEoH7G1Gq8b6qp7zxvBxuSbriF_Zds5npAtfNbXjeccnzXLZ1pXv-OO7tktdVM67Sz7mT63-qLz21Zr4s2_Ljld1H1JOxTE7MPrD0cnuDtnrzfXL5C6YPtzeT8bToJBJ5INQEpQihSKHuAjJ6DzBODcy0QixVlKJSOVoJKWJASVMHgotKC2VLKmIjJRDdrbtXdnmsyXns0XT2rp_maUIgEkEoofOf4NEGKJQCiX2lNhShW2cs2Syla2W2nYZQrZZOvu5dC_JreR6uJ6T_a7-0xrtLD2nfxlfFUiLyQ</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Rouleau, Benoît</creator><creator>Lavoie, Louise</creator><creator>Leblanc, Jacinthe</creator><creator>Moretti, Simon</creator><creator>Collin, Chantal</creator><general>SAGE Publications</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20110901</creationdate><title>Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec</title><author>Rouleau, Benoît ; Lavoie, Louise ; Leblanc, Jacinthe ; Moretti, Simon ; Collin, Chantal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-53e0d290cb07c5efab817bf38a107a434264b1f3e98f042fb52a2e9d43dec6f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Brand names</topic><topic>Drug Information</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Drug stores</topic><topic>Education</topic><topic>Methylphenidate</topic><topic>Pharmaceuticals</topic><topic>Pharmacists</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Polls & surveys</topic><topic>Qualitative research</topic><topic>Safety</topic><topic>Side effects</topic><topic>Switching</topic><topic>Venlafaxine</topic><toplevel>online_resources</toplevel><creatorcontrib>Rouleau, Benoît</creatorcontrib><creatorcontrib>Lavoie, Louise</creatorcontrib><creatorcontrib>Leblanc, Jacinthe</creatorcontrib><creatorcontrib>Moretti, Simon</creatorcontrib><creatorcontrib>Collin, Chantal</creatorcontrib><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Drug information journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rouleau, Benoît</au><au>Lavoie, Louise</au><au>Leblanc, Jacinthe</au><au>Moretti, Simon</au><au>Collin, Chantal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec</atitle><jtitle>Drug information journal</jtitle><stitle>Ther Innov Regul Sci</stitle><date>2011-09-01</date><risdate>2011</risdate><volume>45</volume><issue>5</issue><spage>627</spage><epage>639</epage><pages>627-639</pages><issn>0092-8615</issn><issn>2168-4790</issn><eissn>2164-9200</eissn><eissn>2168-4804</eissn><coden>DGIJB9</coden><abstract>We report on the findings of an original research initiative to explore current gaps that exist in the level of awareness and utilization of Canada's adverse drug reaction (ADR) reporting system among community pharmacists. To understand the level of knowledge and practices related to ADR reporting, a survey was conducted among Quebec pharmacists. Nearly two thirds of respondents had reported at least one ADR in the past, but many did not recognize “lack of effectiveness” as an ADR and were unaware of the minimum requirements for ADR reporting. Events seen as “unexpected, rare, or serious” were most likely to be reported whereas “well-known or common” events or those with “uncertain causality” tended not to be reported. Regarding switching from brand name to generic formulation, two thirds reported that they did not perform special monitoring, yet the same proportion recalled a specific ADR associated with switching, particularly with Effexor XR (venlafaxine XR), Pantoloc (pantoprazole), and Concerta (methylphenidate-OROS). The majority of the current survey participants (Quebec pharmacists) are aware of the ADR reporting system, but underutilization exists.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><doi>10.1177/009286151104500613</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0092-8615 |
| ispartof | Drug information journal, 2011-09, Vol.45 (5), p.627-639 |
| issn | 0092-8615 2168-4790 2164-9200 2168-4804 |
| language | eng |
| recordid | cdi_proquest_journals_910018602 |
| source | SpringerNature Journals; SAGE Journals |
| subjects | Brand names Drug Information Drug Safety and Pharmacovigilance Drug stores Education Methylphenidate Pharmaceuticals Pharmacists Pharmacotherapy Pharmacy Polls & surveys Qualitative research Safety Side effects Switching Venlafaxine |
| title | Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T16%3A39%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reporting%20of%20Adverse%20Drug%20Reactions%20by%20Community%20Pharmacists:%20A%20Qualitative%20Study%20in%20Quebec&rft.jtitle=Drug%20information%20journal&rft.au=Rouleau,%20Beno%C3%AEt&rft.date=2011-09-01&rft.volume=45&rft.issue=5&rft.spage=627&rft.epage=639&rft.pages=627-639&rft.issn=0092-8615&rft.eissn=2164-9200&rft.coden=DGIJB9&rft_id=info:doi/10.1177/009286151104500613&rft_dat=%3Cproquest_cross%3E2551244131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=910018602&rft_id=info:pmid/&rft_sage_id=10.1177_009286151104500613&rfr_iscdi=true |